Trial Profile
Efficacy of ranibizumab and aflibercept in patients with neovascular age-related macular degeneration: A retrospective cohort study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Nov 2016
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary) ; Ranibizumab (Primary)
- Indications Age-related macular degeneration
- Focus Therapeutic Use
- 11 Nov 2016 New trial record
- 02 Nov 2016 Results presented at the 19th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research